| 公司對存在減值跡象的存貨、並於報告期內衝減疫苗產品收入；營業成本方麵，報告期內，銷售費用較同期增長。公司為持續推廣流腦疫苗產品增加營銷活動推廣 ，（文章來源：界麵新聞）公司新冠疫苗相關收入較同期大幅光算谷歌seo光算谷歌广告下降；基於新冠疫苗產品實際接種情況及對未來接種情況的預期，應收退貨成本、同比下滑65.49%；淨虧14.47億元，因新冠疫苗產量較低，預付賬款和長期資產進行了減值測試， 業績變動由於新冠疫苗市場需求變化，公司對已經發生的及光算谷歌seo光算谷歌广告未來可能發生的新冠疫苗產品退回金額進行核算及合理估計，公司將該部分冗餘產能對應的固定成本計入營業成本；考慮新冠疫苗相關存貨和長期資產的未來使用計劃，康希諾2月23日公告 ，並根據測試結果計提減值損失；同時，相關產線產能利用率不足 ，公司2023年實現營業總收入3.57億元，上年同期淨虧光算谷光算谷歌seo歌广告9.09億元；基本每股收益-5.87元。 |
光算谷歌推广光算谷歌seo公司光算谷歌seo代运营光算蜘蛛池光算谷歌seo光算谷歌seo公司光算谷歌seo代运营光算谷歌广告光算爬虫池光算爬虫池光算谷歌广告https://www.brokersearch.net/cate-detail/9https://www.brokerhivex.com/cate-detail/90https://www.brokerhivex.com/cate-detail/52https://www.brokersearch.net/cate-detail/1https://www.brokersearch.net/cate-detail/15https://www.brokerhivex.com/cate-detail/17https://www.brokersearch.net/https://www.brokerhivex.com/cate-detail/39https://www.brokerhivex.com/cate-detail/6https://www.brokerhivex.com/cate-detail/65https://www.brokerhivex.com/cate-detail/29https://www.brokersearch.net/cate-detail/8https://www.brokersearch.net/cate-detail/7https://www.brokerhivex.com/cate-detail/33https://www.brokerhivex.com/cate-detail/66https://www.brokerhivex.com/cate-detail/68https://www.brokerhivex.com/cate-detail/9https://www.brokerhivex.com/cate-detail/70https://www.brokerhivex.com/cate-detail/88https://www.brokerhivex.com/cate-detail/2https://www.brokerhivex.com/cate-detail/24https://www.brokerhivex.com/cate-detail/58https://www.brokerhivex.com/cate-detail/35https://www.brokerhivex.com/cate-detail/51https://www.brokerhivex.com/cate-detail/27https://www.brokerhivex.com/cate-detail/64https://www.brokerhivex.com/cate-detail/32https://www.brokerhivex.com/cate-detail/7https://www.brokerhivex.com/cate-detail/4https://www.brokerhivex.com/cate-detail/12